The Capital Program is estimated to be approximately $100 million per year for 5 years and includes Design, Engineering, Construction Management, Commissioning and Qualification. The program was designed to optimize operations and increase production capacity and capability. Facility types include Office and R&D Facilities, Laboratories, Manufacturing Facilities and Utility and Infrastructure Projects. We established a core team of professionals co-located with client personnel on site; we supplement the core team with home office expertise and support as required. Working in an existing, occupied vaccine and biologics manufacturing campus brings challenges to execute the program, much of which requires fast-track execution over tightly scheduled shutdowns.
Completed strategic projects include optimizing processes and performance, upgrading equipment and facilities and enhancing capacity and capability through the implementation of advanced technologies to meet current and long-term need for vaccines and biologics worldwide. The technical content of the program includes new construction; relocations; implementation of advanced technologies, facility and manufacturing upgrades; equipment installations such as MRI units, 20L Delta V STBR-based Bioreactors, High Pressure Filter Dryer and PSF Skid; HVAC upgrades; process piping revisions and large-scale chilled water system upgrades, to name a few.